2024年12月12日 · Eculizumab (brand names Soliris, Bkemv, Epysqli) is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults, and a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS) in adults and children …

Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica.

2025年2月1日 · Eculizumab injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). This medicine helps reduce red blood cell destruction or breakdown (hemolysis) in patients with PNH.

2007年5月16日 · Eculizumab is a recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Eculizumab injections treat blood diseases called atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. The injections stop your body from breaking down red blood cells and prevent blood cells from clotting.

Soliris is a complement inhibitor indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (1). Do not administer as an intravenous push or...

2024年11月5日 · Soliris (eculizumab) is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults, and a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS) in adults and children who weigh at least 11 pounds (5 kilograms).

Eculizumab is a long-acting humanized monoclonal antibody targeted against complement C5. It inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of MAC. In PNH patients, eculizumab profoundly inhibits haemolysis.

Eculizumab injection is in a group of medications called immunotherapy. Eculizumab injection works by blocking the activity of the part of the immune system that may damage blood cells in people with PNH and that causes clots to form in people with aHUS.

ECULIZUMAB (ek yoo LYE zyoo mab) treats certain blood conditions that can cause low levels of red blood cells (anemia) and blood clots, such as atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).